Citius Oncology, Inc.
CTOR
$0.70
$0.022.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.94M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.94M | -- | -- | -- | -- |
| Cost of Revenue | 789.20K | -- | -- | -- | -- |
| Gross Profit | 3.15M | -- | -- | -- | -- |
| SG&A Expenses | 18.79M | 17.10M | 18.84M | 18.33M | 17.34M |
| Depreciation & Amortization | 573.40K | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.32M | 23.52M | 25.48M | 25.16M | 22.38M |
| Operating Income | -22.38M | -23.52M | -25.48M | -25.16M | -22.38M |
| Income Before Tax | -22.58M | -23.70M | -25.64M | -25.16M | -22.38M |
| Income Tax Expenses | 1.06M | 1.06M | 936.60K | 816.40K | 696.20K |
| Earnings from Continuing Operations | -23.64 | -24.76 | -26.58 | -25.98 | -23.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.64M | -24.76M | -26.58M | -25.98M | -23.08M |
| EBIT | -22.38M | -23.52M | -25.48M | -25.16M | -22.38M |
| EBITDA | -4.68M | -- | -- | -- | -- |
| EPS Basic | -0.31 | -0.34 | -0.37 | -0.37 | -0.33 |
| Normalized Basic EPS | -0.19 | -0.20 | -0.23 | -0.22 | -0.20 |
| EPS Diluted | -0.31 | -0.34 | -0.37 | -0.37 | -0.33 |
| Normalized Diluted EPS | -0.19 | -0.20 | -0.23 | -0.22 | -0.20 |
| Average Basic Shares Outstanding | 308.98M | 293.07M | 284.37M | 280.32M | 276.27M |
| Average Diluted Shares Outstanding | 308.98M | 293.07M | 284.37M | 280.32M | 276.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |